Connect Biopharma Holdings Limited

SAN DIEGO and TAICANG, China, July 05, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage…

Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the…

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued…

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage…

SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note…

– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 – – Company to Host Conference Call Today at 4:30…

— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 —…

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global…

SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage…

Primary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally administered dose showed a numerical improvement, but did not achieve statistical…